Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling

Clinical Cancer Research

Volumn 14, Issue 20, 2008, Pages 6354-6363

  Shochat, Eliezer ^a,b   Rom Kedar, Vered ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Iatromatics   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; DRUG INDUCED DISEASE; MATHEMATICAL MODEL; MONTE CARLO METHOD; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; NEOPLASM; NEUTROPHIL; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; MODELS, THEORETICAL; MONTE CARLO METHOD; NEOPLASMS; NEUTROPENIA; NEUTROPHILS;

EID: 58149176741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0807     Document Type: Article

References (26)

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228-37.
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
3. Bennett CL, Weeks JA, Somerfield MR, et al. Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health services research committee of the American Society of Clinical Oncology. J Clin Oncol 1999;17:3676 -81.
4. Garcia-Carbonero R, Mayordomo JI,Tornamira MV, et al. Granulocyte colonystimulating factorin the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001;93:31-8.
5. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-8.
6. Fenk R, Hieronimus N, Steidl U, et al. Sustained G-CSF plasma levels following administration of peg-filgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006;34:1296-302.
7. Shochat E, Rom-Kedar V, Segel L. G-CSF control of neutrophil dynamics in the blood. Bull Math Biol 2007;69:2299-338.
8. Wang B, Ludden TM, Cheung EN, Schwab GG, Roskos LK. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF)in healthy volunteers. J Pharmacokinet Pharmacodyn 2001;28:321-42.
9. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding studyin women with breast cancer. Ann Oncol 2002;13:903-9.
10. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced mye-losuppression with parameter consistency across drugs. J Clin Oncol 2002;20:4713-21.
11. Limpert E, Stahel WA, Abbt M. Log-normal distributions across the sciences: keys and clues. Bioscience 2001;51:342-52.
12. Erickson LC, Bradley MO, Ducore JM, Ewig RA, Kohn KW. DNA crosslinking and cytotoxicity in normal and transformed human cells treated with anti-tumor nitrosoureas. Proc Natl Acad Sci U S A1980;77:467-71.
13. Sandstrom M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 2005;23:413-21.
14. Minami H, Sasaki Y,WatanabeT, Makoto O. Pharma-codynamic modeling of the entire time course of leukopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res 2001;92:231 -8.
15. Fliedner TM, Graessle D, Paulsen C, Reimers K. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm 2002;17:405-26.
16. Cebon J, Layton JE, Maher D, Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994;86:265-74.
17. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
18. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:4198-214.
19. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood1989;74:1303-7.
20. Woll PJ,Thatcher N, Lomax L, et al. Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lungcancerpatients. J Clin Oncol 2001;19:712-9.
21. PriceTH, Raleigh A, Bowden RA, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 2000;95:3302 -9.
22. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196-205.
23. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and periph-eral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994;84:2923-9.
24. Testa U, Martucci R, Scambia G, et al. Autologous stem cell transplantation: exogenous granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor modulate the endogenous cytokine levels. Blood1997;89:2615-7.
25. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5.
26. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006;46:747-57.